Reports Q4 revenue $994.23M, consensus $986.98M. James Foster, chair, President and CEO, said, “We were pleased with our 2025 financial results, including substantial improvement in DSA net bookings in the fourth quarter that demonstrates the stabilization of the biopharmaceutical demand environment. We are making significant progress on several strategic initiatives that will enable the Company to better capitalize on future growth opportunities, and we remain intently focused on scientific innovation that will reinforce our position as the leader in preclinical drug development.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- CRL Upcoming Earnings Report: What to Expect?
- CRO peers lower after Medpace earnings, comments on cancellations
- Charles River price target raised to $251 from $197 at TD Cowen
- Charles River, Gazi University Faculty of Medicine enter manufacturing pact
- Charles River price target raised to $265 from $200 at Citi